In lung cancer, Aquaporin 3 (AQP3) promotes M2 polarization and upregulates IL-6 secretion via the PPARγ/NF-κB signaling axis, thereby exacerbating glucose metabolic disorders through the IL-6R pathway (210). Here, PPARG is linked to lung cancer.